About Regenxbio
Regenxbio is a company based in Rockville (United States) founded in 2008.. Regenxbio has raised $108.39 million across 16 funding rounds from investors including NIH, HHS and Janus Henderson Investors. The company has 353 employees as of December 31, 2024. Regenxbio offers products and services including ABBV-RGX-314, RGX-202, and RGX-121. Regenxbio operates in a competitive market with competitors including Insitro, BridgeBio, Moderna, ATAI and Forge Biologics, among others.
- Headquarter Rockville, United States
- Employees 353 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Regenxbio Inc.
-
Annual Revenue
$83.33 M-7.66as on Dec 31, 2024
-
Net Profit
$-227.1 M13.81as on Dec 31, 2024
-
EBITDA
$-215.03 M14.27as on Dec 31, 2024
-
Total Equity Funding
$108.39 M (USD)
in 16 rounds
-
Latest Funding Round
$255.95 K (USD), Grant
Sep 15, 2020
-
Investors
NIH
& 15 more
-
Employee Count
353
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Regenxbio
Regenxbio is a publicly listed company on the NASDAQ with ticker symbol RGNX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Regenxbio
Regenxbio offers a comprehensive portfolio of products and services, including ABBV-RGX-314, RGX-202, and RGX-121. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for retinal diseases using AAV vectors.
Therapy for Duchenne muscular dystrophy.
Treatment for Hunter Syndrome.
Unlock access to complete
Unlock access to complete
Leadership Team
34 people
Product Management Team
11 people
Senior Team
9 people
Software Development Team
8 people
Principal Team
6 people
Independent Team
6 people
Operations Team
6 people
Clinical Team
5 people
Unlock access to complete
Funding Insights of Regenxbio
Regenxbio has successfully raised a total of $108.39M across 16 strategic funding rounds. The most recent funding activity was a Grant round of $255.95 thousand completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 16
- Last Round Grant — $255,947
-
First Round
First Round
(21 Jun 2010)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Grant - Regenxbio | Valuation |
investors |
|
| Sep, 2019 | Amount | Grant - Regenxbio | Valuation |
investors |
|
| May, 2015 | Amount | Series D - Regenxbio | Valuation | Brookside Capital , Venrock |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Regenxbio
Regenxbio has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location | |
|
Investment management in biotech, technology, energy, shipping, financials, and litigation sectors.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Regenxbio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Regenxbio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Regenxbio Comparisons
Competitors of Regenxbio
Regenxbio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, Moderna, ATAI and Forge Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Regenxbio
Frequently Asked Questions about Regenxbio
When was Regenxbio founded?
Regenxbio was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Where is Regenxbio located?
Regenxbio is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Who is the current CEO of Regenxbio?
Kenneth Mills is the current CEO of Regenxbio.
Is Regenxbio a funded company?
Regenxbio is a funded company, having raised a total of $108.39M across 16 funding rounds to date. The company's 1st funding round was a Series D of $70.5M, raised on Jun 21, 2010.
How many employees does Regenxbio have?
As of Dec 31, 2024, the latest employee count at Regenxbio is 353.
What is the annual revenue of Regenxbio?
Annual revenue of Regenxbio is $83.33M as on Dec 31, 2024.
What does Regenxbio do?
Regenxbio was founded in 2008 and is headquartered in Rockville, United States. Gene therapies based on adeno-associated virus (AAV) vectors are developed by the company through its proprietary NAV Technology Platform. Programs target rare genetic conditions such as homozygous familial hypercholesterolemia (HoFH) and Mucopolysaccharidosis Type I (MPS I), with additional candidates in development for liver, neurological, and retinal diseases.
Who are the top competitors of Regenxbio?
Regenxbio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Regenxbio offer?
Regenxbio offers ABBV-RGX-314, RGX-202, and RGX-121.
Is Regenxbio publicly traded?
Yes, Regenxbio is publicly traded on NASDAQ under the ticker symbol RGNX.
Who are Regenxbio's investors?
Regenxbio has 16 investors. Key investors include NIH, HHS, Janus Henderson Investors, RTW Investments, and Perceptive Advisors.
What is Regenxbio's ticker symbol?
The ticker symbol of Regenxbio is RGNX on NASDAQ.